+36.8%
FXI vs GSK
+48.7%
-11.9%
-23.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.3% | +0.2% | -1.5% | -1.3% |
| 7D | -2.8% | -3.6% | +0.8% | -2.1% |
| 30D | -5.3% | -5.9% | +0.6% | -4.2% |
| 3M | +0.3% | -4.3% | +4.6% | +1.0% |
| 6M | -4.6% | -10.8% | +6.2% | -2.6% |
| YTD | -9.1% | +1.8% | -10.9% | -10.0% |
| 1Y | -12.0% | +23.5% | -35.4% | -17.0% |
| All | +36.8% | +48.7% | -11.9% | +21.5% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling